Patients who took an aromatase inhibitor for an extra 2 years beyond the 5-year standard treatment received a similar benefit as those who took the inhibitor for an extra 5 years.

Conferences

Genomic analysis revealed differences in the landscape of estrogen receptor-positive cancers when compared with ER+ primary tumors.

Extended observation for adverse reactions following subcutaneously administered trastuzumab (Herceptin, Genentech/Roche) serves as an unnecessary use of health care resources, according to the results of a single-institution study.

Read More

Common menopausal symptoms such as nausea and headaches can be used as predictive tools for adherence to the aromatase inhibitor tamoxifen, according to an analysis of data from the International Breast Cancer Intervention Study (IBIS-1).

-----

Related Content

Read More

A study presented at the 2016 American Society of Clinical Oncology Annual Meeting (June 3-7; Chicago, IL) has found that the costs associated with different breast cancer chemotherapy regimens can vary significantly, regardless of effectiveness.

Read More

News

Patients who took an aromatase inhibitor for an extra 2 years beyond the 5-year standard treatment received a similar benefit as those who took the inhibitor for an extra 5 years.
Breast cancer tumors treated with neoadjuvant chemotherapy may have higher risk of local recurrence after breast-conserving therapy than tumors treated with adjuvant chemotherapy.
Patients with metastatic HER2-negative breast cancer and mutations in BRCA1/2 genes who received a PARP inhibitor had improved PFS by 3 months compared with those treated with chemotherapy.
In a recent study, researchers surveyed surgeons and radiation oncologists on their views of the omission of a certain therapy in treating older women with stage I ER-positive breast cancer.

Quiz

A recent study suggests that which treatment option(s) plus pertuzumab results in improved pathological complete responses in patients with HER2-Positive Breast Cancer?
According to recent research, which therapy reduces the risk of relapse in HER2-positive breast cancer?
According to a recent study, which therapy is most cost-effective for reducing the risk of skeletal events in breast cancer?

Research in Review

Patients with human epidermal growth factor 2 (HER2)-positive breast cancer who undergo induction chemotherapy are likely to convert to HER2-negative disease if residual disease occurs, prompting further systemic therapy, according to research presented at the 2017 ASCO Annual Meeting (June 2-6, 2017; Chicago, IL).

-----

Related Content

Read More

Patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer benefit from an estimated 7 additional months of survival if treated with trastuzumab emtansine rather than the physician’s choice of therapy, according to research published in The Lancet Oncology [published online May 16, 2017; doi:10.1016/S1470-2045(17)30313-3].

-----

Read More

A radiation schedule half the standard course is as safe and effective for patients with breast cancer following a mastectomy, according to a study published in the Journal of Clinical Oncology (published online May 1, 2017; doi:10.1200/JCO.2016.70.7158).

-----

Related Content

Read More

MRI results after percutaneous biopsy for ductal carcinoma in situ (DCIS) often overestimate the extent of breast cancer, resulting in unnecessary mastectomies, according to a presentation at the American Society of Breast Surgeons annual meeting (April 26-30, 2017; abstract 257324).

-----

Related Content

Read More

Subscribe to Breast Cancer